Oxytocin · nasal spray · research use only
Oxytocin dosage, framed for intranasal research.
Oxytocin is studied differently from the injectable peptides most labs source. In social, bonding, and behavioural research it is delivered intranasally, measured in international units (IU) rather than micrograms, and given acutely before a task rather than on a daily schedule. What makes its dosing distinct is that a single administration produces two separate time courses — a fast, large rise in blood and a slow, modest rise in cerebrospinal fluid — so the amount that matters depends on which compartment a study targets. This page lays out the 24 IU reference, that plasma-versus-CSF kinetics story, and why device and technique move the effective dose. It is a laboratory reference, not a human protocol or medical advice.
24 IU is the reference amount
Across the human intranasal-oxytocin literature the dominant single-administration amount is 24 IU, delivered as three 4-IU actuations per nostril — the amount used in the original Syntocinon-based social-cognition and neuroimaging work (Striepens et al., Scientific Reports 2013, 3:3440). Reported study amounts span roughly 20–48 IU, but 24 IU is the anchor most protocols are built against. That figure is a research reference, not a human dose.
Oxytocin bonding research →Two clocks, not one
This is what makes oxytocin dosing distinct. After a 24 IU dose, plasma oxytocin peaks near 15 minutes and returns to baseline by about 75 minutes, while CSF concentrations rise slowly and only reach a significant level around 75 minutes — with essentially no correlation between the two (Striepens 2013). Most studies wait about 45 minutes before starting a task. A protocol has to decide which compartment its endpoint depends on before the timing question even makes sense.
Why timing matters →Why the effective amount is small
Oxytocin is a 1007-Da nonapeptide with a plasma half-life under two minutes but a CSF half-life near 28 minutes (Mens et al., Brain Res 1983) — the reason nasal, not intravenous, delivery is used. Rodent PK work puts nasal bioavailability around 2%, with more than 95% of the oxytocin that reaches the brain arriving by direct nose-to-brain transport rather than via blood. So most of a labelled dose is never the central signal — a reason studies converge on a fixed reference amount rather than scaling upward.
Oxytocin half-life →Device changes the number
The 24 IU figure is tied to a standard spray bottle. Breath-powered nebulizer studies report a comparable central effect at roughly 8–10 IU, because the device deposits more peptide in the posterior nasal cavity where nose-to-brain routes begin (Quintana et al.). The field also adopted a written administration protocol — prime the pump, dose head-upright, one nostril at a time, sniffing gently (Guastella et al., Psychoneuroendocrinology 2013). An oxytocin amount only means something alongside the device and technique that delivered it.
Nasal spray handling →Identity and concentration to confirm
For a nasal-spray format, the verification points are the peptide identity and the labelled concentration per actuation. Titan supplies oxytocin as a ready-to-use metered spray — no bacteriostatic-water reconstitution — characterised by mass-spec identity and HPLC purity against a ≥99% internal target on a lot-matched release sheet, so the IU references on this page map onto a known concentration rather than an assumed one.
See the testing workflow →Research-use framing
Oxytocin in this format has no regulatory approval for human use. The 24 IU reference, the plasma/CSF time course, and the device notes here are reproduced as a laboratory research reference for in-vitro and behavioural-modelling work — not instructions for human use. Titan supplies oxytocin strictly as a research reagent, and nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The intranasal oxytocin dosing reference, in one table.
The variables a behavioural-research protocol weighs for intranasal oxytocin — the reference amount, the split plasma/CSF kinetics that define its timing, the device dependence, and the metered-spray delivery that removes reconstitution. Reproduced as a reference, not a human protocol or medical advice.
- Compound
- Oxytocin — nine-amino-acid neuropeptide, molecular weight ~1007 Da.
- Unit convention
- International units (IU), not micrograms.
- Reference amount
- 24 IU per administration in most human studies (3 × 4 IU per nostril); range ~20–48 IU.
- Plasma time course
- Peaks ~15 min after dosing, returns to baseline by ~75 min (Striepens 2013).
- CSF time course
- Rises slowly; significant only ~75 min, uncorrelated with plasma.
- Half-life
- Plasma <2 min; CSF ~28 min (Mens 1983) — the reason nasal delivery is used.
- Bioavailability
- ~2% nasal (rodent PK); >95% of brain oxytocin arrives by direct nose-to-brain transport.
- Format
- Ready-to-use metered nasal spray, $74.99 — no reconstitution.
Questions researchers ask
Before you order.
- What is the research dosage for intranasal oxytocin?
- The dominant single-administration amount in the human intranasal-oxytocin literature is 24 IU, delivered as three 4-IU actuations per nostril, with reported study amounts spanning roughly 20–48 IU (Striepens et al., Scientific Reports 2013). It is dosed in international units rather than micrograms, and as an acute per-session amount rather than a cumulative daily total. These figures are a laboratory reference, not a human dosing protocol or medical advice.
- Why does intranasal oxytocin have two different time courses?
- After a 24 IU dose, oxytocin in blood peaks near 15 minutes and returns to baseline by about 75 minutes, while cerebrospinal-fluid oxytocin rises slowly and only becomes significant around 75 minutes — and the two are essentially uncorrelated (Striepens 2013). A study has to decide whether its endpoint depends on the peripheral or the central compartment, because they are on different clocks. Most protocols wait about 45 minutes before starting a task.
- Does the nasal spray device affect the effective amount?
- Yes, substantially. The 24 IU reference is tied to a standard spray bottle. Breath-powered nebulizer studies report a comparable central effect at roughly 8–10 IU because they deposit more peptide in the posterior nasal cavity where nose-to-brain transport begins (Quintana et al.). Because response varies so much with technique, the field adopted a written administration protocol (Guastella et al., 2013). An oxytocin amount is only interpretable alongside the device and technique that delivered it.
- Why is oxytocin dosed nasally and acutely rather than daily?
- Oxytocin's plasma half-life is under two minutes and the blood-brain barrier is largely closed to it, so intravenous dosing reaches the brain poorly. Its CSF half-life is far longer (~28 min, Mens et al. 1983), and rodent PK work shows more than 95% of brain oxytocin after nasal dosing arrives by direct nose-to-brain transport. Intranasal delivery is the route that gets a functionally relevant amount centrally, and the brief systemic presence is why research administers it acutely before a task rather than on a standing daily schedule.
- Does Titan's oxytocin nasal spray need reconstitution?
- No. Titan supplies oxytocin as a ready-to-use metered nasal spray, so there is no bacteriostatic-water reconstitution step like an injectable lyophilized vial. Each actuation delivers a fixed volume, which is what makes per-session IU references practical to apply. Storage follows the nasal-spray shelf-life guidance rather than vial reconstitution math.
- Is oxytocin approved for human use in this format?
- No. Titan's oxytocin nasal spray has no regulatory approval for human use. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro and behavioural-modelling laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.